In another example, a type of T cell mimicking nanoparticles (TCMNPs) are developed to neutralize immunosuppressive components like TGF‐β1 and PD‐L1 produced by cancer cells in tumor microenvironment.[55] TCMNPs exhibit higher therapeutic efficacy than PD‐L1 blockade in melanoma treatment (≈50% delay). Here, CD274 is linked to cancer.